Drug intelligence / Profile preview

ABD-320

Development stage: Unknown
Lead developer: Abdera Therapeutics
Modality: Alpha Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

ABD-320 is a targeted radiopharmaceutical biologic therapy developed by Abdera Therapeutics. It is designed to deliver the alpha-emitting radioisotope Actinium-225 to solid tumors that express an undisclosed target, which is described as widely prevalent and associated with poor outcomes in several cancer types. The therapy was engineered using Abdera’s ROVEr platform to optimize tumor uptake and retention while minimizing systemic radiotoxicity. ABD-320 represents the first therapeutic candidate specifically developed for this particular (undisclosed) target[1][6].

Targets

TPBG (Trophoblast glycoprotein)

Beyond the preview

Go deeper on ABD-320.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ABD-320.

Explore the full profile